SK bioscience
SK bioscience, a leading biopharmaceutical company headquartered in South Korea (KR), is renowned for its innovative contributions to vaccine development and biomanufacturing. Founded in 2017, the company has rapidly established itself in the global healthcare landscape, focusing on the research, development, and production of vaccines and biologics. With a commitment to enhancing public health, SK bioscience has achieved significant milestones, including partnerships for COVID-19 vaccine production. Its core offerings, such as the SKYCovione vaccine, exemplify the company's dedication to quality and efficacy, setting it apart in a competitive market. As a key player in the biopharmaceutical industry, SK bioscience continues to expand its operational reach, contributing to global health initiatives and solidifying its position as a trusted name in vaccine innovation.
DitchCarbon Score
How does SK bioscience's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SK bioscience's score of 30 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SK bioscience's reported carbon emissions
In 2023, SK bioscience reported carbon emissions of approximately 5,032,000 kg CO2e for Scope 1 and about 11,866,000 kg CO2e for Scope 2. This reflects a continued commitment to monitoring and managing their carbon footprint. Over the years, the company has demonstrated fluctuations in emissions, with total Scope 1 and 2 emissions reaching about 16,927,000 kg CO2e in 2021 and 18,491,000 kg CO2e in 2022. Notably, in 2021, Scope 3 emissions were reported at approximately 153,405,000 kg CO2e, indicating a significant area for potential improvement in their overall climate strategy. Despite these figures, SK bioscience has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon emissions. The absence of documented reduction targets suggests a need for enhanced climate commitments in line with industry standards. The company’s ongoing efforts to track emissions across all scopes highlight their awareness of the importance of sustainability in the biopharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 428,672,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 103,146,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SK bioscience is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
